Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Machine Learning Prediction of ADHD in Adolescents: Gaming, Sleep, and Sport

sunnuntai 15. marraskuuta 2026 päivittänyt: Yalin Aygun

Predicting Adolescent ADHD: Machine Learning Model of Internet Gaming Disorder, Sleep Quality, and Sport Participation

ADHD is one of the most common mental health conditions in teenagers. It can affect school performance, friendships, and overall well-being. Some everyday habits and lifestyle factors-how much a teenager plays internet games, how well they sleep, and whether they take part in sports-have each been linked to ADHD symptoms. However, these three factors have almost always been studied one at a time, and no study has yet tested whether looking at them together can help predict which teenagers have more severe ADHD symptoms.

This study aims to find out whether internet gaming, sleep quality, and sport participation, when considered together, can predict ADHD symptom severity in adolescents aged 12-17. We will invite 750 teenagers from secondary schools in Malatya, Türkiye, to complete a set of short, anonymous questionnaires about their attention and hyperactivity symptoms, gaming habits, sleep, and sport participation. We will then use machine learning-a type of computer analysis that can detect complex patterns and interactions between many factors at once-to build and test a prediction model.

The main question this study seeks to answer is: Do internet gaming, sleep quality, and sport participation jointly carry information that helps predict ADHD symptoms in teenagers, beyond what is already known from basic characteristics such as age, sex, and socioeconomic status? We are not testing a treatment, and the study does not involve any medication, biological samples, or changes to participants' usual routines. The findings may help schools, families, and health professionals identify teenagers who could benefit from early support and from healthier lifestyle habits. This is an exploratory study; it cannot show cause and effect, and any prediction model would need to be tested in other groups before being used in practice.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Yksityiskohtainen kuvaus

Background and Rationale Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition affecting approximately 5.6% of adolescents worldwide, with substantial downstream consequences for academic achievement, social functioning, and psychological well-being. Although ADHD is multifactorial in etiology, a growing body of evidence indicates that modifiable lifestyle factors-particularly internet gaming disorder (IGD), sleep quality, and sport participation-are individually associated with ADHD symptom severity in adolescence. IGD co-occurs with ADHD at high rates and is hypothesized to share transdiagnostic mechanisms including impulsivity, emotion dysregulation, and maladaptive coping. Poor sleep quality and circadian delay are highly prevalent in adolescents with ADHD and appear bidirectionally linked to symptom severity. Conversely, structured sport participation has been proposed as a potentially protective lifestyle factor, although its effects appear to vary by sport type, dose, and measurement approach.

Critically, these three lifestyle factors have almost exclusively been examined in isolation, and conventional regression models impose linear and additive assumptions that may not reflect the interactive, threshold-dependent, and non-linear relationships likely to characterize them. Machine learning (ML) offers a complementary analytic framework that accommodates high-dimensional interactions, ranks feature importance without a priori constraints on functional form, and can identify subgroups at elevated risk. No study to date has applied an ML framework to test whether IGD, sleep quality, and sport participation jointly carry incremental predictive signal for ADHD symptom severity in adolescents. The present study addresses this gap.

Study Design and Setting This is an observational, cross-sectional, prediction-modeling study conducted among adolescents aged 12-17 years attending secondary schools in Malatya, Türkiye. Data will be collected during the [academic term] using standardized, self-administered instruments under the supervision of trained research assistants. The study is designed to develop and internally validate a multivariable ML model predicting ADHD symptom severity from IGD severity, sleep quality, and multidimensional sport participation, while adjusting for pre-specified sociodemographic, clinical, and lifestyle covariates. The study is exploratory in nature and is not designed to establish causal relationships. The protocol has been approved by the İnönü University Social Sciences Research and Ethics Committee [approval number, date], and written informed consent will be obtained from all participants and their legal guardians prior to data collection. The study will be conducted in accordance with the Declaration of Helsinki and applicable national regulations.

Recruitment and Data Collection Procedures Participants will be recruited through a two-stage sampling strategy. First, secondary schools in the target region will be stratified by school type (public vs. private) and randomly selected. Second, classrooms within participating schools will be randomly selected, and all eligible students will be invited to participate. Data collection will take place in a single session per classroom under standardized conditions, with research assistants available to answer clarification questions without influencing responses. Participants will complete a paper-and-pencil or tablet-based battery comprising the Conners-Wells Adolescent Self-Report Scale (CASS), the Internet Gaming Disorder Scale-Short Form (IGDS9-SF), the Pittsburgh Sleep Quality Index (PSQI), a multidimensional sport participation questionnaire, and a structured sociodemographic and lifestyle form. The full battery is expected to require approximately 30-40 minutes. To minimize social desirability and common-method bias, the order of instruments will be randomized across participants, and anonymity will be emphasized. No biological samples will be collected.

Measures and Instrumentation Primary outcome. ADHD symptom severity will be assessed using the ADHD-specific subscales (cognitive problems/inattention and hyperactivity) of the Turkish-validated CASS. Raw scores will be converted to age- and sex-specific T-scores; both continuous T-scores and a binary indicator (T ≥ 65) will be retained for modeling purposes.

Primary predictors. IGD severity will be measured with the nine-item IGDS9-SF, which maps directly onto DSM-5 criteria and yields a unidimensional total score. Sleep quality will be assessed using the PSQI global score and its seven component scores. Sport participation will be operationalized multidimensionally, including participation status, sport type (team, individual, or both), weekly training hours, years of participation, and competition level.

Covariates. Pre-specified covariates include age, sex, school grade, perceived socioeconomic status, maternal and paternal education, self-reported academic achievement, current ADHD medication use, presence of a chronic health condition limiting sport participation, weekday and weekend recreational screen time, and non-sport physical activity level. All covariates will be entered simultaneously with primary predictors to allow the models to capture interactive and non-linear relationships; no covariate will be dropped on the basis of univariable screening because such filtering can induce bias in predictive modeling.

Machine Learning Analysis Framework Preprocessing. Continuous variables will be standardized (z-scores); categorical variables will be one-hot encoded. Class imbalance for the binary outcome will be addressed during training using class weighting or stratified resampling, with resampling applied only within training folds to prevent information leakage. All preprocessing steps will be embedded within the cross-validation pipeline.

Model development. Several complementary algorithms will be trained to balance interpretability and predictive flexibility, including regularized logistic regression (elastic net), random forest, gradient boosting (XGBoost/LightGBM), and support vector machines. A multilayer perceptron will be considered as a sensitivity analysis. Hyperparameters will be tuned using nested cross-validation with Bayesian optimization or grid search.

Validation strategy. Internal validation will be performed using repeated stratified k-fold cross-validation (k = 5 or 10, with at least 10 repeats). Model performance will be reported as discrimination (area under the receiver operating characteristic curve, area under the precision-recall curve), calibration (calibration slope, intercept, Brier score), and, where relevant, decision curve analysis. For continuous outcomes, root mean squared error, mean absolute error, and R² will be reported. Optimism-corrected performance estimates will be obtained via bootstrap.

Interpretability. Feature importance will be quantified using permutation importance and SHAP (Shapley additive explanations) values. Partial dependence and accumulated local effects plots will be used to characterize non-linear and threshold relationships, with particular attention to potential interactions among IGD, sleep quality, and sport participation. Subgroup analyses will explore whether predictive performance or feature importance differs by sex, age group, and ADHD medication status.

Incremental predictive value. To test whether the three lifestyle factors carry incremental signal beyond covariates, a series of nested models will be compared: (1) covariates only; (2) covariates + IGD; (3) covariates + IGD + sleep quality; and (4) covariates + IGD + sleep quality + sport participation. Differences in discrimination and calibration will be evaluated using DeLong's test for correlated ROC curves, net reclassification improvement, and integrated discrimination improvement.

Sample Size Considerations and Power Analysis The target sample size is 750 adolescents. This target was determined a priori through a combination of conventional power analysis and contemporary guidance for prediction-model development. For the conventional power analysis (G*Power 3.1, linear multiple regression, fixed model, R² increase), assuming a moderate effect size (f² = 0.15), α = 0.05 (two-sided), 80% power, and 10 candidate predictors, the required minimum sample was approximately 118 participants. This confirms that the study is adequately powered for the primary association analyses.

More importantly, for prediction modeling, recent methodological guidance recommends minimum sample sizes of 237 to 694 participants for continuous outcomes to ensure low optimism and precise estimation of model performance. For binary outcomes, rules based on events per candidate predictor and balanced accuracy criteria suggest a need for approximately 500-790 participants. A sample of 750 therefore satisfies both continuous- and binary-outcome modeling requirements, supports repeated stratified k-fold cross-validation with stable performance estimates, and provides sufficient margin for an anticipated 10% data loss as well as for pre-specified subgroup analyses by sex, age group, and ADHD medication status.

Missing Data Management The extent and pattern of missing data will be characterized. If missingness is minimal (< 5%), complete-case analysis will be the primary approach, with multiple imputation by chained equations as a sensitivity analysis. If missingness exceeds 5%, multiple imputation will be the primary approach (m = 20 imputations), and results will be pooled according to Rubin's rules. Missing data will be handled within the cross-validation pipeline to avoid optimism.

Quality Assurance and Data Management Data will be entered into a secure, encrypted REDCap database with predefined range, consistency, and logic checks. A random 10% sample of records will be double-entered and compared to source documents. Data queries will be resolved by the study coordinator in collaboration with the principal investigator. All analytic code will be version-controlled and archived, and a statistical analysis plan will be finalized before database lock. The study will be reported in accordance with the TRIPOD+AI guideline for prediction models.

Reporting and Dissemination Results will be disseminated through peer-reviewed publication and conference presentation, with an emphasis on transparent reporting of model development, validation, and limitations. The final model will not be deployed clinically without external validation in an independent cohort.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

750

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Battalgazi
      • Malatya, Battalgazi, Turkki (Türkiye), +90
        • Selahaddin Eyyubi AİHL (Science and Social Sciences Project School)
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

12 vuotta - 17 vuotta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Todennäköisyysnäyte

Tutkimusväestö

The study population consists of adolescents aged 12-17 years who are currently enrolled in secondary schools in Malatya, Türkiye. Participants are recruited through a two-stage sampling strategy: schools are first stratified by type (public vs. private) and randomly selected, and classrooms within participating schools are then randomly selected, with all eligible students invited to take part. The sample is school-based and community-derived rather than clinically referred, and includes adolescents across the full range of ADHD symptom severity, from no or minimal symptoms to clinically significant levels. No clinical ADHD diagnosis is required for participation. The planned enrollment is 750 adolescents, which provides sufficient power for the planned prediction models and allows for an anticipated 10% data loss as well as pre-specified subgroup analyses by sex, age group, and ADHD medication status. Data are collected at a single time point under standardized conditions.

Kuvaus

Inclusion Criteria:

Adolescents aged 12-17 years at the time of data collection. Currently enrolled in a secondary school in Malatya, Türkiye. Written informed consent obtained (participant assent plus parental/legal guardian consent for minors).

Able to read and understand Turkish and to complete self-administered questionnaires.

No clinical ADHD diagnosis required; adolescents with and without ADHD symptoms are eligible.

Exclusion Criteria:

Age outside 12-17 years. Not currently attending a secondary school. Unable or unwilling to provide consent/assent, or no parental/legal guardian consent.

Visual, hearing, cognitive, or language impairment preventing independent completion of self-report questionnaires.

Any condition or circumstance that, in the investigator's judgment, would compromise participant safety or data integrity.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: CROSS_SECTIONAL

Kohortit ja interventiot

Ryhmä/Kohortti
Adolescents Aged 12-17 Years

Single observational cohort of adolescents aged 12-17 years attending secondary schools in Malatya, Türkiye. All participants complete the same self-administered battery at one time point: the Conners-Wells Adolescent Self-Report Scale (CASS) for ADHD symptoms, the Internet Gaming Disorder Scale-Short Form (IGDS9-SF), the Pittsburgh Sleep Quality Index (PSQI), a multidimensional sport participation questionnaire, and a demographic/lifestyle form. No intervention, medication, biological sample, or change to usual routine is involved. Sport participation, ADHD medication use, and other characteristics are treated as covariates or subgroup variables in the machine learning prediction models, not as separate groups.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
ADHD Symptom Severity: Conners-Wells Adolescent Self-Report Scale (CASS) Inattention and Hyperactivity Subscales
Aikaikkuna: Single time point (baseline assessment). All participants complete the CASS once during the data collection session; no follow-up assessments are planned.

ADHD symptom severity will be assessed using the ADHD-specific subscales (cognitive problems/inattention and hyperactivity) of the Turkish-validated Conners-Wells Adolescent Self-Report Scale (CASS) for adolescents aged 12-17 years. The scale is self-administered under standardized instructions. Raw scores are converted to age- and sex-specific T-scores, with T ≥ 65 indicating clinically significant symptom burden. Both continuous T-scores (primary) and a binary indicator (T ≥ 65 vs. < 65) will be retained for machine learning modeling. The CASS demonstrates acceptable to good internal consistency (Cronbach's α = 0.76-0.87) and established criterion validity against the Conners Parent and Teacher Rating Scales-Revised in Turkish adolescents.

Single time point (baseline assessment). All participants complete the CASS once during the data collection session; no follow-up assessments are planned.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Yalin Aygun, Prof. Dr., Inonu University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Perjantai 1. tammikuuta 2027

Ensisijainen valmistuminen (Arvioitu)

Perjantai 1. tammikuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 1. helmikuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Sunnuntai 15. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Sunnuntai 15. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 19. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 19. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Sunnuntai 15. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 11698

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

De-identified individual participant data will not be shared. This is an investigator-initiated, school-based observational study without dedicated funding or data-sharing infrastructure. The dataset contains self-reported information from minors, and the informed consent/assent procedures did not include permission for broader data sharing beyond the study team. Aggregate results will be reported in peer-reviewed publications.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .